Normal view MARC view ISBD view

TP53 in AML and MDS: The new (old) kid on the block. [Review]

MedStar author(s):

Citation: Blood Reviews. 60:101055, 2023 Jul.PMID: 36841672Department: Hematology & Oncology Fellowship | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Leukemia, Myeloid, Acute | *Myelodysplastic Syndromes | *Myeloproliferative Disorders | Humans | Leukemia, Myeloid, Acute/di [Diagnosis] | Leukemia, Myeloid, Acute/ge [Genetics] | Leukemia, Myeloid, Acute/th [Therapy] | Mutation | Myelodysplastic Syndromes/di [Diagnosis] | Myelodysplastic Syndromes/ge [Genetics] | Myelodysplastic Syndromes/th [Therapy] | Prognosis | Tumor Suppressor Protein p53/ge [Genetics] | Year: 2023 ISSN:

0268-960X

Name of journal: Blood reviewsAbstract: MDS and AML are clonal hematopoietic stem cell disorders of increasing incidence, having a variable prognosis based, among others, on co-occurring molecular abnormalities. TP53 mutations are frequently detected in these myeloid neoplasms and portend a poor prognosis with known therapeutic resistance. This article provides a timely review of the complexity of TP53 alterations, providing updates in diagnosis and prognosis based on new 2022 International Consensus Classification (ICC) and World Health Organization (WHO) guidelines. The article addresses optimal testing strategies and reviews current and arising therapeutic approaches. While the treatment landscape for this molecular subgroup is under active development, further exploration is needed to optimize the care of this group of patients with unmet needs. Copyright © 2023 Elsevier Ltd. All rights reserved.All authors: Bagg A, Fenu EM, Lai C, Marks JA, Wang XFiscal year: FY2024 Digital Object Identifier:

https://dx.doi.org/10.1016/j.blre.2023.101055

Date added to catalog: 2023-07-27

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	36841672	Available		36841672

MDS and AML are clonal hematopoietic stem cell disorders of increasing incidence, having a variable prognosis based, among others, on co-occurring molecular abnormalities. TP53 mutations are frequently detected in these myeloid neoplasms and portend a poor prognosis with known therapeutic resistance. This article provides a timely review of the complexity of TP53 alterations, providing updates in diagnosis and prognosis based on new 2022 International Consensus Classification (ICC) and World Health Organization (WHO) guidelines. The article addresses optimal testing strategies and reviews current and arising therapeutic approaches. While the treatment landscape for this molecular subgroup is under active development, further exploration is needed to optimize the care of this group of patients with unmet needs. Copyright © 2023 Elsevier Ltd. All rights reserved.

English